An internal assessment of FDA's inter-center consultations for combination products has found the process overly cumbersome, but FDA says it is already simplifying access to its IT system, revising instruction manuals, updating its organizational charts and putting out more guidance documents to address the concerns raised in the report.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?